Oncolytics Biotech (ONCY) Competitors $0.57 0.00 (-0.68%) As of 11:59 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ONCY vs. CGEN, KYTX, ACOG, LXEO, IKT, ALEC, EPRX, BDTX, KRRO, and FTLFShould you be buying Oncolytics Biotech stock or one of its competitors? The main competitors of Oncolytics Biotech include Compugen (CGEN), Kyverna Therapeutics (KYTX), Alpha Cognition (ACOG), Lexeo Therapeutics (LXEO), Inhibikase Therapeutics (IKT), Alector (ALEC), Eupraxia Pharmaceuticals (EPRX), Black Diamond Therapeutics (BDTX), Korro Bio (KRRO), and FitLife Brands (FTLF). These companies are all part of the "pharmaceutical products" industry. Oncolytics Biotech vs. Its Competitors Compugen Kyverna Therapeutics Alpha Cognition Lexeo Therapeutics Inhibikase Therapeutics Alector Eupraxia Pharmaceuticals Black Diamond Therapeutics Korro Bio FitLife Brands Compugen (NASDAQ:CGEN) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability, community ranking and analyst recommendations. Which has stronger earnings and valuation, CGEN or ONCY? Compugen has higher revenue and earnings than Oncolytics Biotech. Compugen is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCompugen$27.59M5.45-$18.75M-$0.16-10.53Oncolytics BiotechN/AN/A-$20.56M-$0.29-1.98 Is CGEN or ONCY more profitable? Compugen has a net margin of 2.67% compared to Oncolytics Biotech's net margin of 0.00%. Compugen's return on equity of 2.62% beat Oncolytics Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Compugen2.67% 2.62% 1.36% Oncolytics Biotech N/A -141.15%-84.73% Does the MarketBeat Community favor CGEN or ONCY? Compugen received 148 more outperform votes than Oncolytics Biotech when rated by MarketBeat users. However, 68.51% of users gave Oncolytics Biotech an outperform vote while only 64.24% of users gave Compugen an outperform vote. CompanyUnderperformOutperformCompugenOutperform Votes30964.24% Underperform Votes17235.76% Oncolytics BiotechOutperform Votes16168.51% Underperform Votes7431.49% Does the media refer more to CGEN or ONCY? In the previous week, Compugen and Compugen both had 3 articles in the media. Compugen's average media sentiment score of 1.23 beat Oncolytics Biotech's score of 0.47 indicating that Compugen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compugen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oncolytics Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate CGEN or ONCY? Compugen currently has a consensus target price of $4.00, indicating a potential upside of 137.39%. Oncolytics Biotech has a consensus target price of $4.33, indicating a potential upside of 656.25%. Given Oncolytics Biotech's higher probable upside, analysts clearly believe Oncolytics Biotech is more favorable than Compugen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Compugen 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Oncolytics Biotech 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Do insiders and institutionals hold more shares of CGEN or ONCY? 12.2% of Compugen shares are owned by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are owned by institutional investors. 9.5% of Compugen shares are owned by insiders. Comparatively, 0.1% of Oncolytics Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, CGEN or ONCY? Compugen has a beta of 2.54, meaning that its stock price is 154% more volatile than the S&P 500. Comparatively, Oncolytics Biotech has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500. SummaryCompugen beats Oncolytics Biotech on 13 of the 16 factors compared between the two stocks. Get Oncolytics Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ONCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONCY vs. The Competition Export to ExcelMetricOncolytics BiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$49.61M$6.92B$5.62B$8.58BDividend YieldN/A2.54%5.28%4.17%P/E Ratio-2.128.6227.1919.81Price / SalesN/A262.21408.23154.60Price / CashN/A65.8538.3234.64Price / Book2.126.566.994.65Net Income-$20.56M$143.75M$3.23B$248.05M7 Day Performance59.17%-0.50%-0.18%-0.26%1 Month Performance7.30%10.66%8.61%4.37%1 Year Performance-44.37%3.39%32.26%13.65% Oncolytics Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCYOncolytics Biotech1.4876 of 5 stars$0.57-0.7%$4.33+656.3%-44.0%$49.61MN/A-2.1230Gap DownCGENCompugen2.2461 of 5 stars$1.70-2.3%$4.00+135.3%-18.6%$151.70M$27.59M85.0070Positive NewsGap DownKYTXKyverna Therapeutics2.5223 of 5 stars$3.45+1.8%$18.50+436.2%-74.8%$149.11M$7.03M-1.0296ACOGAlpha Cognition1.7949 of 5 stars$9.17-2.2%$20.00+118.1%N/A$146.90M$2.93M-3.58N/ANews CoverageLXEOLexeo Therapeutics3.7651 of 5 stars$4.38+12.9%$18.50+322.4%-77.5%$145.40M$650K-1.3958Gap UpIKTInhibikase Therapeutics1.4883 of 5 stars$1.95-0.5%$6.50+233.3%+20.9%$144.97M$260K-0.736Positive NewsALECAlector3.3738 of 5 stars$1.44-3.4%$4.00+177.8%-65.5%$143.99M$88.34M-0.85270Short Interest ↑Analyst RevisionEPRXEupraxia Pharmaceuticals2.3124 of 5 stars$3.97+0.8%$10.50+164.5%+43.2%$142.32MN/A-5.5129BDTXBlack Diamond Therapeutics3.4904 of 5 stars$2.48-3.9%$14.60+488.7%-61.1%$141.02M$70M-1.8690Positive NewsKRROKorro Bio3.5549 of 5 stars$14.85+1.8%$102.43+589.8%-67.2%$139.46M$4.82M-1.5770Positive NewsAnalyst RevisionGap DownFTLFFitLife Brands4.2013 of 5 stars$14.19-0.8%$20.50+44.5%-6.1%$133.26M$63.86M16.7920Short Interest ↑ Related Companies and Tools Related Companies Compugen Competitors Kyverna Therapeutics Competitors Alpha Cognition Competitors Lexeo Therapeutics Competitors Inhibikase Therapeutics Competitors Alector Competitors Eupraxia Pharmaceuticals Competitors Black Diamond Therapeutics Competitors Korro Bio Competitors FitLife Brands Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ONCY) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
